The experts collectively emphasized that the presence of antibodies to platelet factor 4 is a key feature and driver of VITT with an adenovirus vector COVID-19 vaccine, which must be considered a specific newly identified syndrome (Fig. 1). Here, PF4 is linked to COVID-19.